Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AbbVie (ABBV)

AbbVie cuts 2026 EPS guidance to $13.76-$13.96 on $216 million Q3 charge

Negative Impact 4 of 5 guidance Written later

AbbVie said third-quarter 2026 results will include $216 million in pre-tax acquired IPR&D and milestones expense, which reduces both GAAP and adjusted diluted EPS by $0.11. The company lowered its guidance accordingly: full-year 2026 adjusted diluted EPS is now $13.76-$13.96, and third-quarter adjusted diluted EPS is $3.73-$3.77. Third-quarter figures are preliminary and have not been finalized.

Key points

  • Q3 2026 acquired IPR&D and milestones expense: $216 million pre-tax, a $0.11 per-share hit to GAAP and adjusted EPS
  • Full-year 2026 adjusted diluted EPS guidance: $13.76-$13.96, down from $13.87-$14.07 before the Q3 charge
  • Q3 2026 adjusted diluted EPS guidance: $3.73-$3.77, down from $3.84-$3.88 before the charge
  • Results for the quarter ended September 30, 2026 remain subject to closing procedures and may differ from these estimates

The filing

CompanyAbbVie (ABBV)
Form8-K, current report
Filed with the SECOct 5, 2026, 4:07 PM ET
Accession number0001551152-26-000030

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.